Search Results - "Mollee, P."

How to diagnose amyloidosis by Mollee, P., Renaut, P., Gottlieb, D., Goodman, H.

“…Amyloidosis is a rare but devastating condition caused by deposition of misfolded proteins as aggregates in the extracellular tissues of the body, leading to…”
Get full text

Correction: HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients by Burgess, M., Chen, Y. C. E., Mapp, S., Blumenthal, A., Mollee, P., Gill, D., Saunders, N. A.

“…A Correction to this paper has been published: https://doi.org/10.1038/s41388-020-01619-y…”
Get full text

HDAC7 is an actionable driver of therapeutic antibody resistance by macrophages from CLL patients by Burgess, M., Chen, Y. C. E., Mapp, S., Blumenthal, A., Mollee, P., Gill, D., Saunders, N. A.

“…Resistance, to therapeutic antibodies used to treat chronic lymphocytic leukemia (CLL) patients is common. Monocyte-derived macrophages (MDMs) are a major…”
Get full text

Catheter-associated bloodstream infection incidence and risk factors in adults with cancer: a prospective cohort study by Mollee, P, Jones, M, Stackelroth, J, van Kuilenburg, R, Joubert, W, Faoagali, J, Looke, D, Harper, J, Clements, A

“…Summary Central venous catheter-associated bloodstream infections (CABSIs) cause considerable morbidity in patients with cancer. We determined the incidence…”
Get full text

Catheter-associated bloodstream infections in adults with cancer: a prospective randomized controlled trial by Mollee, P., Okano, S., Abro, E., Looke, D., Kennedy, G., Harper, J., Clouston, J., Van Kuilenburg, R., Geary, A., Joubert, W., Eastgate, M., Jones, M.

“…A common complication of central venous access devices (CVADs) is catheter-associated bloodstream infection (CABSI). We previously demonstrated that insertion…”
Get full text

Catheter-associated bloodstream infection in patients with cancer: comparison of left- and right-sided insertions by Jones, M., Okano, S., Looke, D., Kennedy, G., Pavilion, G., Clouston, J., Van Kuilenburg, R., Geary, A., Joubert, W., Eastgate, M., Mollee, P.

“…There is limited research on the relationship between side of insertion of central venous catheter (CVAD) and bloodstream infection risk in patients with…”
Get full text

Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia by Cass, S.H., Tobin, J.W.D., Seo, Y.D., Gener-Ricos, G., Keung, E.Z., Burton, E.M., Davies, M.A., McQuade, J.L., Lazar, A.J., Mason, R., Millward, M., Sandhu, S., Khoo, C., Warburton, L., Guerra, V., Haydon, A., Dearden, H., Menzies, A.M., Carlino, M., Smith, J.L., Mollee, P., Burgess, M., Mapp, S., Keane, C., Atkinson, V., Parikh, S.A., Markovic, S.N., Ding, W., Call, T.G., Hampel, P.J., Long, G.V., Wargo, J.A., Ferrajoli, A.

“…Immune checkpoint inhibitors (ICIs) have revolutionized the management of advanced melanoma (AM). However, data on ICI effectiveness have largely been…”
Get full text

Increased FcγRIIB dominance contributes to the emergence of resistance to therapeutic antibodies in chronic lymphocytic leukaemia patients by Burgess, M, Mapp, S, Mazzieri, R, Cheung, C, Chambers, L, Mattarollo, S R, Mollee, P, Gill, D, Saunders, N A

“…Resistance to therapeutic antibodies in chronic lymphocytic leukaemia (CLL) is common. In this study, we show that therapeutic antibodies against CD62L…”
Get full text

International Prognostic Index, Type of Transplant and Response to Rituximab Are Key Parameters to Tailor Treatment in Adults With CD20‐Positive B Cell PTLD: Clues From the PTLD‐1 Trial by Trappe, R. U., Choquet, S., Dierickx, D., Mollee, P., Zaucha, J. M., Dreyling, M. H., Dührsen, U., Tarella, C., Shpilberg, O., Sender, M., Salles, G., Morschhauser, F., Jaccard, A., Lamy, T., Reinke, P., Neuhaus, R., Lehmkuhl, H., Horst, H. A., Leithäuser, M., Schlattmann, P., Anagnostopoulos, I., Raphael, M., Riess, H., Leblond, V., Oertel, S.

“…Tailoring treatment by patient strata based on the risk of disease progression and treatment toxicity might improve outcomes of patients with posttransplant…”
Get full text

Frequency of bowel perforation and impact of bowel rest in aggressive non‐Hodgkin lymphoma with gastrointestinal involvement by Chin, C. K., Tsang, E., Mediwake, H., Khair, W., Biccler, J., Hapgood, G., Mollee, P., Nizich, Z., Joske, D., Radeski, D., Cull, G., Villa, D., El‐Galaly, T. C., Cheah, C. Y.

Get full text

Dual epigenetic targeting with panobinostat and azacitidine in acute myeloid leukemia and high-risk myelodysplastic syndrome by Tan, P, Wei, A, Mithraprabhu, S, Cummings, N, Liu, H B, Perugini, M, Reed, K, Avery, S, Patil, S, Walker, P, Mollee, P, Grigg, A, D'Andrea, R, Dear, A, Spencer, A

“…Therapeutic options are limited for elderly patients with acute myeloid leukemia (AML). A phase Ib/II study was undertaken to evaluate the maximum-tolerated…”
Get full text

The duality of macrophage function in chronic lymphocytic leukaemia by Chen, Y.C.E., Mapp, S., Blumenthal, A., Burgess, M.L., Mazzieri, R., Mattarollo, S.R., Mollee, P., Gill, D., Saunders, N.A.

“…Chronic lymphocytic leukaemia (CLL) is the most common adult leukaemia and, in some patients, is accompanied by resistance to both chemotherapeutics and…”
Get full text

Developing Safe Haematological Monitoring Guidelines for Patients with Myeloma on Bortezomib based Regimens by Woodrow, C, Mollee, P

Get full text

Immunity, Homing and Efficacy of Allogeneic Adoptive Immunotherapy for Posttransplant Lymphoproliferative Disorders by Gandhi, M. K., Wilkie, G. M., Dua, U., Mollee, P. N., Grimmett, K., Williams, T., Whitaker, N., Gill, D., Crawford, D. H.

“…Adoptive immunotherapy using autologous Epstein‐Barr virus (EBV)‐specific cytotoxic T‐lymphocytes (auto‐CTL) can regress posttransplant lymphoproliferative…”
Get full text

Homozygous FCGR3A-158V alleles predispose to late onset neutropenia after CHOP-R for diffuse large B-cell lymphoma by Keane, C., Nourse, J. P., Crooks, P., Nguyen-Van, D., Mutsando, H., Mollee, P., Lea, R. A., Gandhi, M. K.

“…Background Recent reports suggest genetic polymorphisms influence susceptibility to rituximab‐induced late‐onset neutropenia (LON), which in turn may be a…”
Get full text

P16 HEALTH‐RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT‐INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL by Facon, T., Plesner, T., Usmani, S., Kumar, S., Bahlis, N., Hulin, C., Orlowski, R., Nahi, H., Mollee, P., Ramasamy, K., Roussel, M., Jaccard, A., Delforge, M., Karlin, L., Arnulf, B., Chari, A., Pei, H., Gupta, N., Kaila, S., Matt, K., Gries, K., Carson, R., Borgsten, F., Weisel, K., Perrot, A.

Get full text

Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group by Quach, H., Joshua, D., Ho, J., Szer, J., Spencer, A., Harrison, S. J., Mollee, P., Roberts, A. W., Horvath, N., Talulikar, D., To, B., Zannettino, A., Brown, R., Catley, L., Augustson, B., Jaksic, W., Gibson, J., Prince, H. M.

“…The survival of patients with multiple myeloma (MM) has improved substantially since the introduction in the late 1980s of high‐dose chemotherapy (HDT)…”
Get full text

Deliverability and efficacy of R-CHOP chemotherapy in very elderly patients with diffuse large B-cell lymphoma: an Australian retrospective analysis by Millar, A., Ellis, M., Mollee, P., Cochrane, T., Fletcher, J., Caudron, A., Webster, B., Trotman, J.

“…Background Elderly patients with diffuse large B‐cell lymphoma (DLBCL) have an inferior prognosis, due in part to advanced age and pre‐existing comorbidities,…”
Get full text

Addition of etoposide to standard acute myeloid leukaemia induction chemotherapy does not improve survival by Jackson, K., Mollee, P., Morris, K., Kennedy, G.

Get full text

Management of systemic AL amyloidosis: recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group by Weber, N., Mollee, P., Augustson, B., Brown, R., Catley, L., Gibson, J., Harrison, S., Ho, P. J., Horvath, N., Jaksic, W., Joshua, D., Quach, H., Roberts, A. W., Spencer, A., Szer, J., Talaulikar, D., To, B., Zannettino, A., Prince, H. M.

“…Systemic AL amyloidosis is a plasma cell dyscrasia with a characteristic clinical phenotype caused by multi‐organ deposition of an amyloidogenic monoclonal…”
Get full text